home / stock / apls / apls articles
NEW YORK, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP: Do you, or did you, own shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APL...
NEW YORK, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Apellis Pharmaceuticals, Inc. ("Apellis" or ...
BENSALEM, Pa., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on ...
News, Short Squeeze, Breakout and More Instantly...
Apellis Pharmaceuticals Inc. Company Name:
APLS Stock Symbol:
NASDAQ Market:
Apellis Pharmaceuticals Inc. Website:
WALTHAM, Mass., July 18, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS) today announced that the company will host a conference call and webcast to discuss its second quarter 2024 financial results on Thursday, August 1, 2024, at 8:30 a.m. ET. To access ...
Late-breaking presentation shows SYFOVRE® (pegcetacoplan injection) demonstrated visual function benefit on prespecified endpoint in GALE long-term extension study WALTHAM, Mass., July 09, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that six ...
WALTHAM, Mass., June 28, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a negative opinion on the marketing authorization application (MAA) of i...